ストックスクリーナーアプリを入手
16.42
1.42%
0.23
前日終値:
$16.19
開ける：
$16.35
24時間の取引高:
59,085
Relative Volume:
0.17
時価総額：
$488.08M
収益：
-
当期純損益:
$11.77M
株価収益率:
28.38
EPS:
0.5785
ネットキャッシュフロー:
$-19.23M
1週間 パフォーマンス:
-1.74%
1か月 パフォーマンス:
-10.95%
6か月 パフォーマンス:
-23.38%
1年 パフォーマンス:
+27.98%
1日の値動き範囲:
$16.11
$16.52
1週間の範囲:
$15.45
$17.03
52週間の値動き範囲:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
TRML を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
16.42 | 488.08M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-15 | 開始されました | Jefferies | Buy |
| 2023-12-04 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-17 | 開始されました | Truist | Buy |
| 2023-10-31 | 開始されました | Guggenheim | Buy |
| 2023-10-25 | 開始されました | Piper Sandler | Overweight |
| 2022-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
すべてを表示
Tourmaline Bio Inc (TRML) 最新ニュース
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings - Defense World
Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Releases Updated Corporate Presentation - TipRanks
Tourmaline Bio Elects Directors and Ratifies Auditor - TipRanks
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE - Defense World
Nuveen Asset Management LLC Has $1.55 Million Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
BNP Paribas Financial Markets Reduces Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Jane Street Group LLC Cuts Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $291,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey
H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India
H.C. Wainwright maintains $50 target on Tourmaline Bio stock - Investing.com
Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World
Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World
BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia
Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria
BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria
Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com
Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com
Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News
Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com
Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com
Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks
Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq
Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com
Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia
Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus
Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire
Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan
Tourmaline shares edge lower despite phase 2 trial results By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times
Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq
Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan
Tourmaline Bio Inc (TRML) 財務データ
収益
当期純利益
現金流量
EPS
Tourmaline Bio Inc (TRML) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):